Pyxis Oncology (NASDAQ:PYXS) Downgraded by William Blair to “Market Perform”

William Blair cut shares of Pyxis Oncology (NASDAQ:PYXS) from an outperform rating to a market perform rating in a research report sent to investors on Thursday, MarketBeat.com reports.

Other equities analysts have also issued research reports about the stock. Royal Bank of Canada restated an “outperform” rating and set a $7.00 target price on shares of Pyxis Oncology in a research report on Thursday, September 19th. Stephens began coverage on Pyxis Oncology in a report on Friday, November 8th. They issued an “overweight” rating and a $13.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research note on Friday, August 16th. Finally, Stifel Nicolaus initiated coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They issued a “buy” rating and a $10.00 price objective for the company. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Pyxis Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Pyxis Oncology Price Performance

PYXS opened at $1.90 on Thursday. The firm has a market cap of $112.99 million, a P/E ratio of -1.84 and a beta of 1.27. Pyxis Oncology has a 1-year low of $1.35 and a 1-year high of $6.85. The company has a 50 day simple moving average of $3.64 and a two-hundred day simple moving average of $3.61.

Institutional Investors Weigh In On Pyxis Oncology

Institutional investors and hedge funds have recently modified their holdings of the business. MetLife Investment Management LLC increased its stake in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after purchasing an additional 5,484 shares during the period. Pier 88 Investment Partners LLC increased its position in shares of Pyxis Oncology by 7.0% during the third quarter. Pier 88 Investment Partners LLC now owns 121,610 shares of the company’s stock worth $446,000 after acquiring an additional 7,910 shares during the period. Fullcircle Wealth LLC bought a new stake in shares of Pyxis Oncology during the second quarter valued at approximately $40,000. SG Americas Securities LLC bought a new position in Pyxis Oncology in the first quarter worth approximately $59,000. Finally, Jane Street Group LLC increased its holdings in Pyxis Oncology by 40.8% during the 3rd quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock worth $182,000 after purchasing an additional 14,349 shares during the period. 39.09% of the stock is owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.